The US Food and Drug Administration says it needs more evidence of efficacy before it can approve Swiss firm Arpida's intravenous iclaprim for the treatment of complicated skin and skin structure infections.
Commenting on the complete response letter, company chief executive Jurgen Raths said: "after the negative recommendation of the Advisory Committee of last November, the FDA opinion comes as no surprise. We now aim to develop a viable roadmap to approval in close consultation with the FDA. The drastic cost saving measures that we've recently implemented should buy us sufficient time to consider and develop strategic options for progressing iclaprim's development."
Last year, Arpida announced plans to reduce its workforce by up to 60 employees, while consulting external experts to determine the future development of iclaprim (Marketletter December 8, 2008).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze